For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Theravance Biopharma R&d Ip, LLC

USPTO Granted Patents = 262

CIPO Patents = 121

EPO Patents = 58

Trademarks = 4

Forward Citations = 1,190

Loading Chart...

Loading Chart...

218 inventors (with patents filed for the assignee):

Adam D Hughes (78 out of 136 patents)

Melissa Fleury (74 out of 92 patents)

Daniel D Long (42 out of 104 patents)

4. Miroslav Rapta (40 out of 62 patents)

5. Paul Ross Fatheree (40 out of 144 patents)

6. Venkat R Thalladi (37 out of 42 patents)

7. Robert Murray McKinnell (35 out of 73 patents)

8. Roland Gendron (35 out of 75 patents)

9. Erik Fenster (28 out of 29 patents)

10. Cameron Smith (28 out of 33 patents)

11. Ryan Hudson (23 out of 41 patents)

12. Lan Jiang (22 out of 64 patents)

13. Gary E L Brandt (21 out of 22 patents)

14. Lori Jean Patterson (20 out of 32 patents)

15. Lori Jean Van Orden (19 out of 22 patents)

262 patents: Sort by Forward Citations

1. 12398135 - Dimethyl amino azetidine amides as JAK inhibitors (2025-08-26),

2. 12384761 - Imidazolo indazole compounds as JAK inhibitors (2025-08-12),

3. 12358931 - 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor (2025-07-15),

4. 12351561 - Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof (2025-07-08),

5. 12285417 - Methods for treating chronic obstructive pulmonary disease (2025-04-29),

6. 12258316 - Biphenyl compounds useful as muscarinic receptor antagonists (2025-03-25),

7. 12239638 - Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound (2025-03-04),

8. 12172994 - Pyrimidine compound as JAK kinase inhibitor (2024-12-24),

9. 12122773 - Crystalline hydrate of a JAK inhibitor compound (2024-10-22),

10. 12048692 - Methods for treating chronic obstructive pulmonary disease (2024-07-30),

11. 12016835 - Neprilysin inhibitors (2024-06-25),

12. 11919888 - Neprilysin inhibitors (2024-03-05),

13. 11878977 - JAK inhibitors containing a 4-membered heterocyclic amide (2024-01-23),

14. 11858898 - Crystalline freebase forms of a biphenyl compound (2024-01-02),

15. 11851443 - Neprilysin inhibitors (2023-12-26),

THERAVANCE BIOPHARMA R&D IP, LLC is a biopharmaceutical company that focuses on the discovery, development, and commercialization of medicines for various therapeutic areas. They are dedicated to improving patient lives by advancing innovative treatments. With a strong emphasis on research and development, THERAVANCE BIOPHARMA R&D IP, LLC strives to bring novel therapies to market to address unmet medical needs.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

262 Patents

#6 in South San Francisco, CA

#348 in California

#1,573 in US

#3,224 in the World

South San Francisco, CA, United States of America

Theravance Biopharma R&d Ip, LLC

Forward Citations = 1,190

218 inventors:

Adam D Hughes (78 out of 136 patents)

Melissa Fleury (74 out of 92 patents)

Daniel D Long (42 out of 104 patents)

4. Miroslav Rapta (40 out of 62 patents)

5. Paul Ross Fatheree (40 out of 144 patents)

Please report any incorrect information to support@idiyas.com

Loading…